2 completed, 1 terminated. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow Galantamine ER: new trials by email Literature Review of Galantamine ER trials Research Report on Galantamine ER
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia Galantamine ER, Memantine XR - Schizophrenia, Schizoaffective Disorder | Phase 2 | Terminated | Sheppard Pratt Health System | 3 | 2014-09-01 | 2017-11-09 |
| Effect of Galantamine on Smoking Abstinence Galantamine ER - Nicotine Addiction | Phase 2 | Completed | University of Pennsylvania | 13 | 2012-02-01 | 2017-12-26 |
| Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease galantamine ER - Alzheimer's Disease | Phase 3 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 83 | 2004-05-01 | 2011-05-20 |
Alzheimer Disease (1) · Cognitive Dysfunction (1) · Psychotic Disorders (1) · Schizophrenia (1) · Smoking (1) · Tobacco Use Disorder (1)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1) · Sheppard Pratt Health System (1) · University of Pennsylvania (1)
United States (2)
Maju M. Koola, MD (1) · Rebecca Ashare, Ph.D. (1)